These data combined with our present results support the rationale to test, in leukemia models, the combined treatment of DNMT1 selective inhibitors with already approved “epidrugs”, such as HDAC inhibitors, or preclinically investigated molecules such as LSD1 inhibitors. The gene discussed is HDAC9; the disease is leukemia.